Firma immatics biotechnologies, Autor bei PR-Web

Immatics Announces Board of Directors Additions Following Public Listing on NASDAQ

Posted on 9. July 2020 by Firma immatics biotechnologies Posted in Research / Development Tagged attack, cancer, cell, chambr, clinical, discovery, financial, immatics, immunotherapies, new, patients, securities, statements, tcr, with

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced changes to its Board of Directors in conjunction with its recent listing on NASDAQ. Michael Atieh, Paul Carter, […]

Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics

Posted on 30. June 2020 by Firma immatics biotechnologies Posted in General Tagged arya, aryas, cancer, cell, cells, cms, immatics, patients, perceptive, power, securities, statements, svb, tcr, with

Arya Sciences Acquisition Corp. (NASDAQ: ARYA or “Arya”), a special purpose acquisition company sponsored by Perceptive Advisors, and Immatics Biotechnologies GmbH (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced […]

Immatics Appoints Cedrik Britten as Chief Medical Officer

Posted on 4. June 2020 by Firma immatics biotechnologies Posted in General Tagged biontech, cancer, cell, clinical, financial, immatics, immunotherapies, immunotherapy, new, patients, research, statements, tcr, therapy, with

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced that Cedrik Britten, MD, has been appointed as Chief Medical Officer (CMO) effective June 1, 2020. Trained as a […]

Immatics Announces Business Combination with Arya Sciences Acquisition Corp., Creating a Publicly Listed Leader in TCR-based Immunotherapies

Posted on 17. March 2020 by Firma immatics biotechnologies Posted in Research / Development Tagged arya, cancer, dievini, hermes, immatics, market, patients, perceptive, prospectus, revenue, statements, svb, tcr, tcrs, with

Upon successful completion of the business combination, Immatics will receive up to approximately $148 million of cash held within Arya’s trust account Leading institutional investors commit $104 million of cash through a common stock private investment in public equity (“PIPE”) led […]